SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

1.22 (USD) • At close September 18, 2024
Bedrijfsnaam SELLAS Life Sciences Group, Inc.
Symbool SLS
Munteenheid USD
Prijs 1.22
Beurswaarde 78,485,649
Dividendpercentage 0%
52-weken bereik 0.5 - 1.9
Industrie Biotechnology
Sector Healthcare
CEO Dr. Angelos M. Stergiou M.D., ScD h.c.
Website https://www.sellaslifesciences.com

An error occurred while fetching data.

Over SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the

Vergelijkbare Aandelen

CASI Pharmaceuticals, Inc. logo

CASI Pharmaceuticals, Inc.

CASI

6.76 USD

Great Elm Group, Inc. logo

Great Elm Group, Inc.

GEG

1.88 USD

Silver Spike Investment Corp. logo

Silver Spike Investment Corp.

SSIC

11.74 USD

BioVie Inc. logo

BioVie Inc.

BIVI

2.9 USD

Lantern Pharma Inc. logo

Lantern Pharma Inc.

LTRN

3.91 USD

Neuronetics, Inc. logo

Neuronetics, Inc.

STIM

0.945 USD

ImmuCell Corporation logo

ImmuCell Corporation

ICCC

3.6 USD

Mustang Bio, Inc. logo

Mustang Bio, Inc.

MBIO

0.254 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)